

## **Original Research Article**

### **EPIDEMIOLOGICAL PATTERN OF ADULT HAEMATOLOGICAL MALIGNANCIES IN A TERTIARY HOSPITAL IN CROSS RIVER STATE, NIGERIA**

1Akaba Kingsley, 2 Nwogoh Benedict 1Bassey Okon Bassey, 1Ofonime Effiong

1 Department of Haematology and Blood Transfusion, University of Calabar Teaching Hospital, Calabar.

2. Department of Haematology and Blood Transfusion, University of Benin Teaching Hospital, Benin City, Edo State.

[akaba\\_kingsley@yahoo.com](mailto:akaba_kingsley@yahoo.com)

Corresponding Author

AKABA KINGSLEY

DEPARTMENT OF HAEMATOLOGY AND BLOOD TRANSFUSION, UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR

[akaba\\_kingsley@yahoo.com](mailto:akaba_kingsley@yahoo.com)

#### **ABSTRACT**

**Background:** Haematological malignancies are associated with increase morbidity and mortality in our environment. The pattern and distribution of diagnosed haematological cancers vary with age, sex, geographical location, and ethnicity. The epidemiology of adult haematological malignancies have not been described in our institution. This study aim to describe demographic distribution of affected persons and the types of haematological malignancies seen in our institution.

**Methods:** This is a 10-year (2009-2018) retrospective study of all adult haematological malignancies seen at the University of Calabar Teaching Hospital, Calabar (UCTH). Data of year of presentation and diagnosis, age, gender, tribe, state of residence, place of origin of the patients and type of haematological malignancy were extracted from the hospital cancer registry, haematology medical records and from patients casenotes. The data were collated into a Microsoft Excel 2016 spreadsheet and analysed with IBM SPSS Version 22. The results were presented using descriptive statistics (frequencies and percentages), and graphical charts.

**Result:** A total of 1314 cases of malignancies were seen during the study period. One hundred and thirty eight (7.8%) were adult haematological malignancies. Their ages ranged from 16 to 74 years. They include 73(52.9%) males and 65(47.10%) females with a male to female ratio of 1.1:1. Majority of the patients 105 (76.09%) are indigenes of Cross River State. The prevalence of lymphoid malignancies was higher than myeloid (76.81% vs 23.91%). Chronic lymphocytic leukaemia (CLL) was the commonest haematological

malignancy (36, 26.09%) followed by Non-Hodgkin's lymphoma (NHL) 28 (20.29%) while Myelodysplastic syndrome (MDS) and Burkitt's lymphoma 2 (1.45%) each were the least.

**Conclusion:** This study has highlighted the burden and epidemiological pattern of HM in our institution and would serve as a terms of reference for further studies on the topic and a tool for raising awareness on the disease burden.

**Keywords:** Hematological malignancies, Epidemiology, Calabar

## INTRODUCTION

Haematological malignancies (HM) are heterogeneous group of neoplasm of clonal origin, arising from haemopoietic tissue (bone marrow and reticuloendothelial tissue)<sup>[1]</sup>. This spectrum of disease ranges from the pre-leukaemic (myelodysplasia), leukaemic, lymphoma to multiple myeloma. The etiology of these malignancies is largely unknown however interplay of genetic mutations, environmental risk factors and infectious agents have been implicated in the pathogenesis of the disease.

Malignancies including HM are becoming public health challenge and disease of global priority due to the associated increase in morbidity and mortality<sup>[2]</sup>. Global prevalence of HM is estimated to account for 6.5% of all cancer worldwide<sup>[3]</sup>. Non-Hodgkin's Lymphoma (NHL) is said to be 2.7 % of all cancers and 2.4 % of all mortality from cancer worldwide. Leukaemia accounted for 2.5 % of all cancers and 3.2 % of all deaths and Multiple Myeloma (MM) was said to be 0.8 % of all cancers and 1.0 % of cancer deaths, while Hodgkin's Lymphoma (HL) represented 0.5 % of all cancers and 0.5 % of cancer deaths<sup>[4]</sup>. However, there are variation in the epidemiology from one geographical region to another.

Hematologic malignancies make up a fifth of the most commonly occurring cancers and the second leading cause of cancer mortality<sup>[5, 6]</sup>. Leukaemia was the fifth most common cause of cancer deaths in men and the sixth most common in women in the United States in a 5-year study between 2007 and 2011<sup>[7]</sup> and in the United Kingdom, haematological malignancy is said to make up 63.2% with male 55.7% and female 44.3%<sup>8</sup>. In Sub-Saharan Africa it is third most common malignancy in males and sixth in females<sup>[9,10]</sup>. Similarly, in Nigeria it accounts for 17.4-18.05% of all cancer in Nigeria and it is the third and fifth in both male and female respectively<sup>[9,10]</sup>. A study conducted in Northern Nigeria showed prevalence 19.8% with male preponderance and chronic leukaemia predominantly<sup>[11]</sup>. Another study in the Southwest Nigeria reported a prevalence of 18.05% of all cancer with male preponderance and NHL predominantly<sup>[10]</sup>. Similar study conducted in Benin South-South of Nigeria, showed a prevalence of 17.4% with male preponderance and NHL predominantly<sup>[12]</sup>. There is paucity of information on the epidemiology of adult haematological malignancies in our environment, thus aim of this study was to describe the epidemiological pattern of HM in Calabar with a view to reawaken the consciousness of burden and pattern of distribution of Adult haematological malignancies in the sub region.

## MATERIALS & METHODS:

This is a 10-year (2009-2018) retrospective study of all adult haematological malignancies seen at the University of Calabar Teaching Hospital, Calabar (UCTH), Calabar. The hospital is a 600-bed tertiary health institution that renders specialist care to its host community and environs. It serves as a referral center for its neighbouring states which include Akwa-Ibom, and Ebonyi state as well Cameroun.

The study population consisted of all patients with haematological malignancies diagnosed at the University of Calabar Teaching Hospital from August 2009 to December 2018. Data for the study were obtained from the Medical Records Department, haematology day-care clinic attendance register, the admission/discharge register, death register and the Cancer Registry

domicile at the department of histopathology. The diagnoses of HM were made medical consultants based on clinical and laboratory investigations of the patients included peripheral blood film and bone marrow examinations, histopathological assessment, immunohistology and immunohistochemistry on tissue specimen. Patients with inconclusive diagnoses were excluded from the study. Collected data include those who were diagnosed but were not managed in the hospital and those who passed on before their histology results were ready. Data that were collected included the date of presentation, the age, gender, tribe, state of residence, place of origin of the patients and type of malignancy. Adult was defined as ages of 16 and above.

The data were collated into Microsoft Excel 2016 spreadsheet and analysed with the IBM SPSS Version 22. The results were summarized using simple descriptive statistics (frequencies and percentages), and presented as tables and graphical charts.

## **RESULTS**

A total of 1314 cases of malignancies were seen over the ten-year period (August 2009 to December 2018). One hundred and thirty eight (10.5%) were adult with haematological malignancies. Their ages ranged from 16 to 84 years. The modal age group was the 6<sup>th</sup> decade of life as in table 1. They comprised 73 (52.90%) males and 65 (47.10%) females giving a male to female ratio of 1.1:1.

Majority of the patients 105 (76.09%) are indigenes of Cross River State while the remaining 33 (23.91%) hails from others parts of the country but are majorly resident in Cross River State as shown in table 2. The annual incidence of HM was variable across the years of the study. The least was in 2012 and the highest peak was in 2017 as shown in figure 1.

The top five common HM during the study period were CLL 33 (23.9%), NHL 32 (23.2%), CML 24 (17.4%), HL 20 (14.5%) and MM 17 (12.3%). The least were Burkitts and ALL both had a frequency of 2 (1.4%) each as shown in figure 2.

Table 3 shows the distribution of HM by age. CLL recorded a peak in the 6<sup>th</sup> decade and none case was recorded before the fifth decade of life. CML was recorded in persons between the 3<sup>rd</sup> and 8<sup>th</sup> decade of life with a peak in the 4<sup>th</sup> decade. NHL was reported in all decades of life except in the 5<sup>th</sup> decade. Peak incidence was in the 6<sup>th</sup> decade. HL was seen across all age group except in the 6<sup>th</sup> decade and after the 7<sup>th</sup> decade of life. The two cases of MDS were seen after the 6<sup>th</sup> decade of life. All cases of ALL and AML were reported in persons below 50 years of age. Similarly, Burkitts lymphoma was reported in relatively younger age groups.


Table 4 shows the distribution of the haematological malignancies by gender and age. The prevalence of CLL, CML, MM and Burkitts lymphoma were relatively higher in females while ALL, AML, MDS, Hodgkin's lymphoma and NHL were commoner in the males. Table 5 shows the distribution of various HM for each year of the study.

**Table 1: Showing the various age range and frequency of haematological malignancies**


<b>AGE RANGE</b>	<b>FREQUENCY</b>	<b>PERCENTAGE</b>
10-19	8	5.80
20-29	20	14.49
30-39	15	10.87
40-49	19	13.77
50-59	36	26.09
60-69	24	17.39
70-79	14	10.14
80-89	2	1.45
<b>TOTAL</b>	<b>138</b>	<b>100</b>

**Table 2: Showing the location residence of the patients and frequency of haematological malignancies.**

<b>LOCALITY</b>	<b>FREQUENCY</b>	<b>PERCENTAGE</b>
ABI	4	2.90
IKOT EKPENE	6	4.35
BEKWARA	5	3.62
BOKI	3	2.17
CALABAR	43	31.16
AKWA IBOM	16	11.59
IKOM	25	18.12
OBUBRA	6	4.35
AKAMPKA	11	7.97
OBUDU	8	5.80
UGEPI	6	4.35
YALA	5	3.62
<b>TOTAL</b>	<b>138</b>	<b>100.00</b>



**Figure 1: Showing a 10 years review of haematological malignancies in UCTH**



**Figure 2: showing the prevalence of haematological malignancies in UCTH**

**Table 3: Showing the frequency and age range distribution of various haematological malignancies**

<b>HAEMATOLOGICAL MALIGNANCIES</b>	<b>10-19</b>	<b>20-29</b>	<b>30-39</b>	<b>40-49</b>	<b>50-59</b>	<b>60-69</b>	<b>70-79</b>	<b>≥80</b>
<b>Acute Lymphoblastic Leukemia</b>	2	1	0	1	0	0	0	0
<b>Chronic Lymphocytic Leukemia</b>	0	0	0	7	11	8	8	2
<b>Acute Myeloid Leukemia</b>	0	1	1	1	0	0	0	0
<b>Chronic Myeloid Leukemia</b>	0	5	8	4	6	3	1	0
<b>MDS</b>	0	0	0	0	1	1	0	0
<b>Multiple Myeloma</b>	0	0	0	4	6	6	1	0
<b>Hodgkin's Lymphoma</b>	3	5	3	4	0	2	2	0
<b>Non-Hodgkin's Lymphoma</b>	2	5	3	0	13	3	3	0
<b>Burkitt's Lymphoma</b>	0	1	1	0	0	0	0	0
<b>Total</b>	<b>7</b>	<b>18</b>	<b>16</b>	<b>20</b>	<b>37</b>	<b>23</b>	<b>15</b>	<b>2</b>



**Table 4: Showing the frequency and sex distribution of various haematological malignancies**

<b>HAEMATOLOGICAL MALIGNANCIES</b>	<b>FREQUENCY</b>		<b>TOTAL (%)</b>
	<b>MALE (%)</b>	<b>FEMALE (%)</b>	
<b>Acute Lymphoblastic Leukemia</b>	4 (5.48)	0 (0.00)	4 (2.90)
<b>Chronic Lymphocytic Leukemia</b>	17 (23.29)	19 (29.23)	36 (26.09)
<b>Acute Myeloid Leukemia</b>	3 (4.11)	0 (0.00)	3 (2.17)
<b>Chronic Myeloid Leukemia</b>	11 (15.07)	16 (24.62)	27 (19.57)
<b>Myelodysplastic Syndrome</b>	2 (2.74)	0 (0.00)	2 (1.45)
<b>Multiple Myeloma</b>	4 (5.48)	13 (20.00)	17 (12.32)
<b>Hodgkin's Lymphoma</b>	10 (13.70)	9 (13.85)	19 (13.77)
<b>Non-Hodgkin's Lymphoma</b>	22 (30.14)	6 (9.23)	28 (20.29)
<b>Burkitt's Lymphoma</b>	0 (0.00)	2 (3.08)	2 (1.45)
<b>TOTAL</b>	73 (52.90)	65 (47.10)	138 (100)

**Table 5: Showing various haematological malignancies and yearly distribution**

<b>HAEMATOLOGICAL MALIGNANCIES</b>	<b>2009</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>
<b>Acute Lymphoblastic Leukemia</b>	0	1	0	1	0	0	1	0	1	0
<b>Chronic Lymphocytic Leukemia</b>	2	4	3	1	2	6	4	3	7	4
<b>Acute Myeloid Leukemia</b>	0	0	1	0	0	1	0	0	0	1
<b>Chronic Myeloid Leukemia</b>	2	2	0	0	4	3	2	8	4	2
<b>MDS</b>	0	0	0		0	0	0	0	0	2
<b>Multiple Myeloma</b>	1	1	0	1	0	3	0	3	3	5
<b>Hodgkin's Lymphoma</b>	0	1	1		0	4	4	1	5	3
<b>Non-Hodgkin's Lymphoma</b>	1	2	1	1	0	4	8	3	6	2
<b>Burkitt's Lymphoma</b>	0	0	0	0	0	0	0	1	1	0
<b>Total</b>	8	11	7	4	6	21	19	18	31	16

## DISCUSSION

In this study, Adult HM constitute 10.5% of all malignancies recorded during the period of review. This was similar to rates published in studies conducted in Morocco<sup>[13, 14, 15]</sup> and was slightly higher than the study in United State which reported prevalence of 9.3%<sup>[16]</sup>. The difference in prevalence of HM reflects the wide variation in the epidemiology of HM. The variability of risk factors from one locality to another, health seeking behaviour, availability of consultant specialist to make appropriate diagnosis contribute to the prevalence rate of the community. Availability and accessibility to cancer preventive and control measures may contribute to the relatively lower rate reported in the US.

The study also showed that the prevalence of adult haematological malignancy were more in those residing in Calabar urban followed by Ikom, Akwa Ibom, Akamkpa respectively with least observed in Boki. This pattern maybe attributed to their wvrelative proximity to the health facility and occupational exposure. For instance the hospital is located at Calabar Municipality giving ease of access to those living within the hospital environs whereas, Ikom is approximately 6 hours drive to the state capital where the facility is situated. The predominant occupation in Ikom is cocoa farming and this increases the exposure of the population to organo-phosphorus compounds, insecticides, and pesticides. The same applies to other cities involved in this study.

We showed the annual pattern of distribution of adult HM during the period of review. A peak was observed in 2017 with least incidence in 2012 and the widest difference between consecutive years was between 2016 and 2017. The variation in annual incidence may be attributed in part to frequent industrial actions in the hospital which limits patient access to specialized care. The increase in the recent years is partly due to increased awareness of the availability of haematologist in the institution. The institution now runs a resident programme in haematology and have recruited more haematologist making it easier to access such specialized services.

This study revealed that the age range of adult HM was 16 - 84 years with individual malignancies having varying peak ages. This was similar to the study conducted in Morocco but was at variance with other studies conducted elsewhere in Nigeria<sup>[13, 19, 20]</sup>. Majority of the adult HM was observed among patients age >40 years (70.3%). This is biologically explainable due to the multiple hit theory which suggest that the cumulative effect of genetic assault manifest over time<sup>[21, 22]</sup>.

There is also male preponderance with male to female ratio of 1:1.1. This finding is similar with the general observation in scientific publication that the prevalence of most HM is commoner in male than female<sup>[5]</sup>. Onwvasigwe *et al*<sup>[23]</sup> also reported similar finding in Enugu South Eastern Nigeria. However when the HM were considered individually, females had higher prevalence of CLL, MDS and MM. Our finding is similar to reports from France and United Kingdom where male to female ratio was 1.2:1 and 1.3:1 respectively<sup>[17, 18]</sup>. The high prevalence of CLL in female was similar to what was reported in the North Central and South Western parts of Nigeria by Babatunde *et al*<sup>[10]</sup> and Salawu *et al*<sup>[19]</sup>. Also, a similar study conducted in South-South Nigeria showed female preponderance.

Lymphoid malignancies were 76.81% [20]. This is at akin with other studies conducted within and outside Africa [13, 17, 18]. In this study, chronic leukaemia was more than acute leukaemia. This finding was similar to reports by previous published studies [30, 31, 32]. CLL was the most common (26.09%) followed by NHL (20.29%), CML (19.57%), HL (13.77%), MM (12.32%), ALL (2.90%), AML (2.17%) with MDS and Burkitt's lymphoma having same value (1.45%) this is similar to a study conducted in Morrocco, Northern Africa [13] but at variance with other studies within Nigeria the variation could be attributed to the various study design [9, 10, 12].

The median age for CLL is 54.5 years. This was higher than those observed in Asian [24 - 26] and western countries [27 - 29] with female preponderance which is similar to other studies conducted within Nigeria [10, 19, 20] but is at variance with other studies conducted within and outside Africa [13].

Acute leukaemia had a male preponderance with ALL making up 2.90% and AML 2.17% this differed from other studies reported in Northern and Southern Nigeria [9,10]. Similar prevalence of ALL was reported by Elidrissi *et al* [13] but a higher prevalence of AML. This highlights the slight variation from one locality to another.

NHL is the second most common lymphoid malignancy constituting 20.29% with a median age of 55 years and male preponderance. This is similar to the study conducted by Babatunde *et al* in the North-Central of Nigeria and somewhat similar to study conducted outside Nigeria [10], in Eastern Morocco. Other Nigerian based studies [13, 19, 20] which reported a higher prevalence for NHL.

CML accounted for 19.57% of HM with female more affected than male in the ratio 1.3:1. The median age was within the 30-39years. This is similar to the observation by Higlaund *et al* [33] but was at variance with other studies conducted in South Africa and Nigeria by Louw and Boma *et al* respectively [34, 35].

MM accounted for 12.32% of all adult HM with male to female ration of 1:3.25. This was slightly higher than other study conducted elsewhere in Nigeria but similar to study conducted by Elidrissi *et al* in Morocco [13]. The relatively higher prevalence in our study may be attributed to the fact that cross riverarians are predominantly farmers some of whom are exposed to agrochemicals including organophosphates. The people are also exposed to petrochemical pollutions as an oil producing state These agents have been implicated to have a causal relationship in pathogenesis of myeloma

Hodgkin's lymphoma (HL) accounted for 13.8% of all adult HM with male to female of 1.1:1. HL affects all age groups but had bimodal peaks. The first peak was in young adults (20-29 years) and the second and highest peak 40-49 year. This contrasted studies of develop countries with age peaks of 20-34 years and 55-74years. The variation may be associated with variation in exposure to infection with EBV in children between these countries [37, 38]. Association of HL with malaria endemicity may also contribute to the differences in the epidemiological pattern. Our findings was similar to those of Babatunde *et al* [10] and Oluwasola *et al* [39]. However Omoti *et al* in South-South Nigeria, and some studies in Europe reported relatively lower peaks [20, 37].

MDS contribute 1.45% of HM with modal age at onset of 50-69 years. MDS is usually a diagnosis of exclusion and there is paucity of information on MDS in our environment. A high index of suspicion is necessary for its diagnosis as it presents commonly as refractory anaemia which may be misunderstood for other differentials of chronic anaemia. Salawu et al<sup>[19]</sup> reported a somewhat similar prevalence of 1.9%. Also in Europe, a prevalence of 1.24% but a lower value was reported in Northern Africa<sup>[13, 37]</sup>.

The strength of this study is that it is the first study from our institution on the epidemiology of HM. However it has several limitation inherent in the study design. Being retrospective in nature, information bias is inevitable. A number of cases may have been missed out due to lack of proper documentation. It is possible that the study may have underestimated the burden of HM in our environment because the health sector suffered repeated prolonged industrial actions which may have limited patients' access to care.

## CONCLUSION

This study has highlighted the burden and epidemiological pattern of HM in our institution and would serve as a terms of reference for further studies on the topic and a tool for raising awareness on the disease burden. There is need for further studies to establish causal relationship between HM and environment exposures in our sub region.

## REFERENCE

1. Rodriguez-Abreu D, Bordoni A, and Zucca E. Epidemiology of Haematological Malignancies. *Ann Onco* 2007; 18 (1): 13-18.
2. Hoffbrand AV, Pettit JE, and Moss PA. The Genetics of Haematological Malignancies. In: *Essential Haematology*. 4th edition, 2001; 145-161
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2014;136(5):E359–86. doi: 10.1002/ijc.29210. [[PubMed](#)] [[CrossRef](#)]
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. *CA: A Cancer Journal for Clinicians*. 2008;58:71–96. [[PubMed](#)]
5. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. *JAMA Oncol* 2017;3:524-48. doi:10.1001/jamaoncol.2016.5688.
6. Burns R, Leal J, Sullivan R, Luengo-Fernandez R. Economic burden of malignant blood disorders across Europe: A population-based cost analysis. *Lancet Haematol* 2016;3:e362-70.
7. Cohen J, Pivodic L, Miccinesi G, Onwuteaka-Philipsen BD, Naylor WA, Wilson DM *et al*. International study of the place of death of people with cancer: A population-level comparison of 14 countries across 4 continents using death certificate data. *Br J Cancer* 2015;113:1397-404.
8. Korubo K I, Okoye H C, Efobi C C. The economic burden of malignant and premalignant hematological diseases in Southern Nigeria. *Niger J Clin Pract* 2018;21:1396-402

9. Nwannadi IA, Alao OO, Bazuaye GN, Halim NK, Omoti CE. The epidemiology of haematological malignancies at the university of Benin teaching hospital: A ten year retrospective study. *Internet J Epidemiol* 2010;9:2.
10. Babatunde A, Amiwero C, Olatunji P, Durotoye I. Pattern of haematological malignancies in Ilorin, Nigeria: A ten year review. *Internet J Haemat* 2008;5:1-7
11. Ochaka J E, Ezra D J, Obadiah D D, Ayuba Z, *et al* Prevalence and type of haematological malignancies among adults in a tertiary hospital in Jos-Nigeria: a sixteen-year retrospective analysis *Highland Medical Research Journal* 2017 ; 17(2): 92-96
12. Omoti CE, Imiere EO. Trends in the pattern of leukaemia incidence in a tertiary health center in Nigeria: 1990-2004. *J Med Biomed Res* 2006;5:44-9.
13. Mounia E E, Manal E E, Redouane B, Meryem O & Mohammed B. Distribution and features of haematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years *BMC Cancer* 2016; 16:159-169. DOI 10.1186/s12885-016-2205-5.
14. Bouchbika Z, Haddad H, Benchakroun N, Kotbi S, Megrini A, Bourezgui H, et al. Cancer incidence in Morocco: report from Casablanca registry 2005-2007. *Pan Afr Med J.* 2013;16(1):31
15. Tazi MA, Er-Raki A, Benjaafar N. Cancer incidence in Rabat, Morocco:2006–2008. *Ecancermedicalsecience.* 2013;7:338
16. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin.* 2014;64(1):9–29.
17. Leclair SJ, Rodak BF. The new WHO nomenclature: lymphoid neoplasms. *Clin Lab Sci.* 2002;15(1):55–9.
18. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A. Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004. *Rev Epidemiol Sante Publique.* 2009;57(3):151–8
19. Salawu L, Bolarinwa RA, Durosini MA. Chronic lymphocytic leukaemia: A-twenty years experience and problems in Ile-Ife, South-Western Nigeria. *Afr Health Sci* 2010;10:187-92.
20. Omoti C E, Nwannadi A I, Obieche J C, Olu-Eddo N A. The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study. *The Pan African Medical Journal.* 2012;11:10. doi:10.11604/pamj.2012.11.10.403
21. Coussens LM, Werb Z. Inflammation and cancer. *Nature.* 2002; 420(6917):860–7.
22. Hernández L, Terradas M, Camps J, Martín M, Tusell L, Genescà A. Aging and radiation: bad companions. *Aging Cell.* 2015;14(2):153–61.
23. Onwuasigwe CN, Aniebue PN, and Ndu AC. Spectrum of Paediatric Malignancies in Eastern Nigeria (1989-1998). *West Afr J Med* 2002; 21(1): 31-33.
24. Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, et al. Diagnosed hematological malignancies in Bangladesh-a retrospective analysis of over 5000 cases from 10 specialized hospitals. *BMC Cancer.* 2014;14(1):438
25. Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. *Eur J Haematol.* 2001;67(3):152–7.

26. Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, et al. Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. *Leuk Lymphoma*. 2012;53(10):1961–5.
27. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood*. 2010;116(19):3724–34
28. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. *Br J Cancer*. 2011;105(11):1684–92
29. Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, et al. Diagnosed hematological malignancies in Bangladesh—a retrospective analysis of over 5000 cases from 10 specialized hospitals. *BMC Cancer*. 2014;14(1):438.
30. Shamebo M. Acute Leukaemia in Adult Ethiopians in a Teaching Hospital. *Ethiop Med J*. 1994; 32(1): 17-25.
31. Williams CKO, Bamigboye EA. Estimation of Incidence of Human Leukaemia Subtypes in an Urban African Population. *Onco* 1983; 40: 381-386.
32. Cartwright RA, McNally RJ, and Rowland DJ. The Descriptive Epidemiology of Leukaemia and Related Conditions in Parts of The United Kingdom 1984-1994. London Leukaemia Research Fund.
33. Martin Höglund, Fredrik Sandin, Bengt Simonsson Epidemiology of chronic myeloid leukaemia: an update. *Annals of hematology* 2015;94:241-247
34. Vernon J Louw. Chronic myeloid leukaemia in South Africa. *Journal of haematology* 2013; s75-s78
35. Boma PO, Durosinmi MA, Adediran IA, Akinola NO, Salawu L. Clinical and prognostic features of Nigerians with chronic myeloid leukemia. *The Nigerian Postgraduate Medical Journal* 2006, 13(1):47-52.
36. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A. Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004. *Rev Epidemiol Sante Publique*. 2009;57 (3):151–8
37. Armstrong A, Alexander F, Cartwright R, Angus B, Krajewski A, Wright D, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. *Leukemia*. 1998;12 (8):1272–6
38. McNally R, Rowland D, Roman E, Cartwright R. Age and sex distributions of hematological malignancies in the UK. *Hematol Oncol*. 1997;15(4):173–89
39. Oluwasola AO, Olaniyi JA, Otegbayo JA, Ogun GO et al., A Fifteen-year Review of Lymphomas in a Nigerian Tertiary Healthcare Centre. *J Health Popul Nutr*. 2011; 29(4): 310–316.